Phase 3
Completed N=28
Carnitine Supplementation and Skeletal Muscle Function
Source: ClinicalTrials.gov NCT02692235 ↗Enrolled (actual)
28
Serious AEs
0.0%
Results posted
May 2019
Primary outcomePrimary: Blood Inflammatory Marker — 2.6; 1.8; 2.9; 1.7 mg·L^-1
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Research project objectives The primary aim of the current research project is to use carnitine supplementation as the anti-inflammatory intervention for exploring the relationship between inflammation and associated with aging reduction of skeletal muscle mass.
Hypothesis The carnitine supplementation modulates the blood cytokines concentration. Anti-inflammatory intervention delay the reduction of skeletal muscle mass associated with aging
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Inflammatory Marker |
2.6; 1.8; 2.9; 1.7 | — |
| SECONDARY Lipid Metabolites |
233; 221; 221; 196; 69; 68 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects with no history of gastrointestinal disorders, cardiovascular disease or hypertension.
Exclusion Criteria
- Subjects having any illnesses and a history of gastrointestinal disorder, cardiovascular disease, hypertension, liver and renal disease, diabetes, cancer, alcoholism or other metabolic diseases.
Data sourced from ClinicalTrials.gov (NCT02692235). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.